Insider buying
~$89K34K sh @ $2.59
Traded Nov 18 · filed 1 day later
The CEO of Trisalus Life Sciences paid $89K out of pocket for Trisalus Life Sciences shares. 2 other people at Trisalus Life Sciences bought some too, in the same month.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 17, 2026 · Filed Nov 19, 2026
A Trisalus Life Sciences director paid $22K out of pocket for Trisalus Life Sciences shares. 2 other people at Trisalus Life Sciences bought some too, in the same month. It was the first purchase in 6 months.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$22,000
Shares × reported transaction price
<$25K
+13.8%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 6 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 2 earlier confirmed purchases
3 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
7 days after results of Nov 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $2.30 on Nov 17, 2026, within 2% of its 52-week low, after a 46% drop over the previous 30 trading days
52-week range $2.27 (Nov 16, 2026) to $7.50 (Dec 11, 2025), 0% of the way up, from 251 adjusted closes. 30 trading days earlier: $4.27 on Oct 6, 2026. Describes the past only, not a forecast
RSI 27, 46% under its 200-day average, 42% under its 50-day average, 69% below the 52-week high, 20-day volatility 116% a year, against the S&P 500: −31 points over 1 month, −53 points over 3 months, −27 points over 6 months
From the adjusted closes up to Nov 17, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Insider buying
Traded Nov 18 · filed 1 day later
The CEO of Trisalus Life Sciences paid $89K out of pocket for Trisalus Life Sciences shares. 2 other people at Trisalus Life Sciences bought some too, in the same month.
Insider buying
Traded Nov 17 · filed 2 days later
The CEO of Trisalus Life Sciences paid $71K out of pocket for Trisalus Life Sciences shares. 2 other people at Trisalus Life Sciences bought some too, in the same month. It was the first purchase in 6 months.
Richard Marshak (Chief Commercial Officer) sold ~$1.3K of Trisalus Life Sciences
Automatic saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.